Edition:
United States

Spectrum Pharmaceuticals Inc (SPPI.OQ)

SPPI.OQ on NASDAQ Stock Exchange Global Select Market

19.65USD
4:00pm EDT
Change (% chg)

$-0.70 (-3.44%)
Prev Close
$20.35
Open
$20.35
Day's High
$20.45
Day's Low
$19.57
Volume
709,477
Avg. Vol
528,920
52-wk High
$23.50
52-wk Low
$6.90

Chart for

About

Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved... (more)

Overall

Beta: 1.98
Market Cap(Mil.): $2,076.94
Shares Outstanding(Mil.): 104.06
Dividend: --
Yield (%): --

Financials

  SPPI.OQ Industry Sector
P/E (TTM): -- 244.89 34.04
EPS (TTM): -0.54 -- --
ROI: -12.97 -5.30 13.11
ROE: -16.69 -6.83 15.11

BRIEF-Spectrum Pharmaceuticals Reports Q1 Non-GAAP Loss Per Share $0.15

* SPECTRUM PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PIPELINE UPDATE

May 03 2018

BRIEF-Spectrum Pharmaceuticals Enters Into A Next-Generation Sequencing Companion Diagnostic Partnership With Thermo Fisher Scientific

* SPECTRUM PHARMACEUTICALS ENTERS INTO A NEXT-GENERATION SEQUENCING COMPANION DIAGNOSTIC PARTNERSHIP WITH THERMO FISHER SCIENTIFIC

May 01 2018

BRIEF-Shrotriya May Sell Up To 1 Mln Shares Of Spectrum Pharmaceuticals' Common Stock

* RAJESH C. SHROTRIYA - SHROTRIYA MAY SELL UP TO 1 MILLION SHARES OF SPECTRUM PHARMACEUTICALS' COMMON STOCK BETWEEN MARCH 26 AND JUNE 29 - SEC FILING‍​ Source text: (https://bit.ly/2pKokJc) Further company coverage:

Mar 27 2018

BRIEF-Spectrum Pharma Q4 Loss Per Share $0.29

* SPECTRUM PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 AND FULL YEAR 2017 FINANCIAL RESULTS AND PIPELINE UPDATE

Mar 06 2018

BRIEF-Spectrum Pharmaceuticals Announces Appointment Of William Ashton To Its Board

* SPECTRUM PHARMACEUTICALS ANNOUNCES APPOINTMENT OF WILLIAM L. ASHTON TO ITS BOARD OF DIRECTORS

Feb 27 2018

BRIEF-Spectrum Pharmaceuticals Announces Rolontis Met The Primary Endpoint In The Phase 3 Advance Study

* SPECTRUM PHARMACEUTICALS ANNOUNCES ROLONTIS™ (EFLAPEGRASTIM) MET THE PRIMARY ENDPOINT IN THE PHASE 3 ADVANCE STUDY

Feb 05 2018

BRIEF-Spectrum Pharmaceuticals Says Expect To File A Registration Application (Bla) With FDA For Rolontis

* SPECTRUM PHARMACEUTICALS SAYS EXPECT TO FILE A REGISTRATION APPLICATION (BLA) WITH FDA FOR ROLONTIS IN Q4 2018 - SEC FILING Source text for Eikon: (http://bit.ly/2EmWf09) Further company coverage:

Jan 08 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $121.45 -0.59
Pfizer Inc. (PFE.N) $36.30 -0.16
Novartis AG (NOVN.S) CHF75.60 +0.10
Merck & Co., Inc. (MRK.N) $61.18 -0.10
Roche Holding Ltd. (ROG.S) CHF216.45 --
Roche Holding Ltd. (RO.S) CHF219.60 -1.20
Abbott Laboratories (ABT.N) $61.75 -0.39
Bayer AG (BAYGn.DE) €96.39 -0.51
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €67.71 -0.60

Earnings vs. Estimates